ProCE Banner Activity

Alliance 051701: Randomized Phase II/III Trial of DA-EPOCH-R ± Venetoclax in Patients With Previously Untreated Double-Hit Lymphoma

Slideset Download
Conference Coverage
The addition of venetoclax to DA-EPOCH-R in patients with previously untreated double-hit lymphoma was associated with excess treatment-related toxicity and mortality.

Released: December 16, 2021

Expiration: December 15, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation